舒思与维思通治疗精神分裂症的对照研究  

Study on Quetiapine Fumarate and Risperidone in the treatment of schizophrenia

作　　者：刘增龙[1] 韩建生[1] 成玉敏[1] 颜敏[1] 周会爽[1] 

机构地区：[1]河北省第六人民医院,河北保定071000

出　　处：《河北职工医学院学报》2006年第2期14-15,21,共3页Journal of Hebei Medical College for Continuing Education

摘　　要：目的比较舒思和维思通治疗分裂症的疗效和副作用。方法共纳入符合CCMD-3精神分裂症诊标准的患者60例,随机分为两组,分别予以舒思和维思通治疗8周。采用阳性症状和阴性症状量表(PANSS)评定疗效。不良反应症量表(TESS)评定副作用。结果舒思的总有效率为87%,显效率为66%,无效率为13%。与维思通相比起效慢。第三周才产生疗效。其副作用主要是嗜睡和活动减少。结论舒思是一种安全有效的抗精神病药。Objective To compare the efficacy and side effects of Quetiapine Fumarate and Risperidone in the treatment of schizophrenia. Methods 60 patients with schizophrenia according to CCMD - 3 were involved in this study, they were randomly assigned to Quetiapine Fumarate group （ n = 30 ） and Rispeidone group （ n = 30 ） and treated for 8 weeks. PANSS was adopted to evaluate the efficacy. TESS was adopted to evaluate side effects. Results The overall effective rate ,the obvious effective rate and the inefficacy rate of Quetiapine Fumarate were 87% ,65% and 13% respectively,but the effect time of Quetiapine Fumarate was at the third week, and lower than that of Risperdone, its side effects were more sleep and less activity. Conclusion Quetiapine Fumarate is an effective and safe antipsychiotic drug.

关 键 词：舒思 维思通 精神分裂症 疗效 

分 类 号：R749.3[医药卫生—神经病学与精神病学]